Hallgeir Rui, MD, PhD

Interim Co-Director, MCW Cancer Center; WBCS Endowed Professor of Breast Cancer Research; Director, MCW Tissue Bank; Professor and Vice Chair of Research, Pathology

Locations

Pathology & Laboratory Medicine
TBRC

Contact Information

General Interests

Breast Cancer Research

Education

MD, University of Oslo, Oslo, Norway
PhD, Pathology, University of Oslo, Oslo, Norway

Biography

Hallgeir Rui, MD, PhD is internationally recognized for his research on hormone signaling in breast cancer, and has a strong track record of leadership, mentoring and collaboration. He is the WBCS Endowed Professor of Breast Cancer Research at the Medical College of Wisconsin (MCW), with his primary appointment in the Department of Pathology, and a secondary appointment to the Department of Pharmacology & Toxicology. In addition, Dr. Rui serves as the Associate Director of Basic Science and Shared Resources at the MCW Cancer Center. With his past experience as a Program Leader and Shared Resource Director at the NCI-designated Sidney Kimmel Cancer Center at Thomas Jefferson University, Dr. Rui brings valuable experience to the MCW Cancer Center efforts toward NCI-designation. Dr. Rui serves on the Breast Cancer Translational Research Committee of NRG Oncology.

Research Interests

Breast Cancer

Cytokine receptors

Hormones: Estrogen, growth, glucocorticoid, steroid

Endocrinology

Prolactin and Prolactin receptors

Jak2, Stat5, Stat5a, Stat5b

Immunohistochemistry

Pathology

Biomarkers

Early detection

Tissue microarray

Mouse modeling

EGFR, Her2, ErbB2

Neuronatin is a modifier of estrogen receptor-positive breast cancer incidence and outcome.

(Plasterer C, Tsaih SW, Peck AR, Chervoneva I, O'Meara C, Sun Y, Lemke A, Murphy D, Smith J, Ran S, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Mitchell EP, Bergom C, Joshi A, Auer P, Prokop J, Rui H, Flister MJ.) Breast Cancer Res Treat. 2019 Aug;177(1):77-91.
The p52 isoform of SHC1 is a key driver of breast cancer initiation.

(Wright KD, Miller BS, El-Meanawy S, Tsaih SW, Banerjee A, Geurts AM, Sheinin Y, Sun Y, Kalyanaraman B, Rui H, Flister MJ, Sorokin A.) Breast Cancer Res. 2019 06 15;21(1):74.
Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3.

(Schlaak RA, Frei A, Schottstaedt AM, Tsaih SW, Fish BL, Harmann L, Liu Q, Gasperetti T, Medhora M, North PE, Strande JL, Sun Y, Rui H, Flister MJ, Bergom C.) Am J Physiol Heart Circ Physiol. 2019 Jun 01;316(6):H1267-H1280.
Identification of a Rat Mammary Tumor Risk Locus That Is Syntenic with the Commonly Amplified 8q12.1 and 8q22.1 Regions in Human Breast Cancer Patients.

(Plasterer C, Tsaih SW, Lemke A, Schilling R, Dwinell M, Rau A, Auer P, Rui H, Flister MJ.) G3 (Bethesda). 2019 05 07;9(5):1739-1743.
An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

(Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.) Cancer Cell. 2019 01 14;35(1):33-45.e6.
Mapping Mammary Tumor Traits in the Rat.

(Flister MJ, Joshi A, Bergom C, Rui H.) Methods Mol Biol. 2019;2018:249-267.
Exploring drivers of gene expression in the Cancer Genome Atlas.

(Rau A, Flister M, Rui H, Auer PL.) Bioinformatics. 2019 01 01;35(1):62-68.
Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling.

(Tran TH, Utama FE, Sato T, Peck AR, Langenheim JF, Udhane SS, Sun Y, Liu C, Girondo MA, Kovatich AJ, Hooke JA, Shriver CD, Hu H, Palazzo JP, Bibbo M, Auer PW, Flister MJ, Hyslop T, Mitchell EP, Chervoneva I, Rui H.) Clin Cancer Res. 2018 12 15;24(24):6355-6366.
Control of CCND1 ubiquitylation by the catalytic SAGA subunit USP22 is essential for cell cycle progression through G1 in cancer cells.

(Gennaro VJ, Stanek TJ, Peck AR, Sun Y, Wang F, Qie S, Knudsen KE, Rui H, Butt T, Diehl JA, McMahon SB.) Proc Natl Acad Sci U S A. 2018 10 02;115(40):E9298-E9307.
CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion.

(Jiao X, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, Guerrero-Rodriguez S, Addya S, Sicoli D, Mu Z, Zhang G, Stucky A, Zhang X, Cristofanilli M, Fatatis A, Gray JW, Zhong JF, Prendergast GC, Pestell RG.) Cancer Res. 2018 04 01;78(7):1657-1671.
Comparative Survival Analysis of Invasive Breast Cancer Patients Treated by a U.S. Military Medical Center and Matched Patients From the U.S. General Population.

(Ru Y, Liu J, Fantacone-Campbell JL, Zhu K, Kovatich AJ, Hooke JA, Kvecher L, Deyarmin B, Kovatich AW, Cammarata F, Hueman MT, Rui H, Mural RJ, Shriver CD, Hu H.) Mil Med. 2017 11;182(11):e1851-e1858.
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth.

(Pestell TG, Jiao X, Kumar M, Peck AR, Prisco M, Deng S, Li Z, Ertel A, Casimiro MC, Ju X, Di Rocco A, Di Sante G, Katiyar S, Shupp A, Lisanti MP, Jain P, Wu K, Rui H, Hooper DC, Yu Z, Goldman AR, Speicher DW, Laury-Kleintop L, Pestell RG.) Oncotarget. 2017 Oct 10;8(47):81754-81775.

Hallgeir Rui, MD, PhD